PD-L1 has been shown to be expressed in various cancers—including gastric cancer, esophageal cancer, renal cell carcinoma, ovarian cancer, and hepatocellular carcinoma—and the overexpression of this immunomodulating ligand has been associated with poorer clinical outcomes. The gene discussed is CD274; the disease is cancer.